At a glance
ClinicalIndex Comparison RecordN/ACompleted· 206 enrolled
Drug / intervention
AKL-T01device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Software Treatment for Actively Reducing Severity of ADHD as Adjunctive Treatment to Stimulant (STARS-ADHD Adjunctive)
In Brief
A clinical study evaluating AKL-T01 for Attention Deficit Hyperactivity Disorder. Completed, enrolled 206 participants across 2 sites.
Detailed Summary
The purpose of this study is to determine the effects of combining AKL-T01 (with AKL-X01 symptom tracking) as adjunctive treatment to stimulant medication, and to understand the effects of AKL-T01 treatment (with AKL-X01 symptom tracking) in participants not recently on medication.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention Deficit Hyperactivity Disorder
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
First PostedAug 2018
Enrollment StartDec 2018
Primary CompletionSep 2019
TodayJul 2026
First PostedAug 28, 2018
Enrollment StartDec 28, 2018
Primary CompletionSep 23, 2019
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 7.8 years ago
Interventions
AKL-T01device
AKL-T01 multitasking digital treatment. AKL-T01 multitasking treatment employs perceptual discrimination attention/memory task as well as a continuous motor "driving" task.